Digital Health Platform Achieves SOC 2 Milestone in Booming Sector
Healthcare Platform Clears Major Security Milestone After Independent Audit
Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale
Houston ALS Biotech Coya Eyes 2028 Approval Path
Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target
DarioHealth AI Platform Targets 10-15% Revenue Growth from Existing Clients
AI Engine Delivers Engagement Gains as Recurring Revenue Outlook Climbs
Pet Odor Market Ignites BioLargo Consumer Comeback
BioLargo re-enters the booming U.S. pet odor control market with a direct-to-consumer CupriDyne brand, building on proven demand while advancing water treatment and medical technologies for retail investors.Cleantech Co. Relaunches Pet Brand Under Its Own Control
BioLargo Inc. (BLGO:OTCQX) unveils plans to reintroduce its enormously popular CupriDyne-based pet odor products to the consumer market. This time, the company says it will own the brand and do it its own way. This article is issued on behalf of Dyadic International Inc. Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation
Contributed Technical Analyst Opinion Technical Analyst Stewart Thomson takes a look at Dyadic International Inc. (DYAI:NASDAQ) as it secures strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors.
Satellos Bioscience Delivers Promising DMD Data With Fast Track Win
Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity.Biotech With Muscle Disease Drug Uncovers Results in Trial Data
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) shares promising data from its study evaluating a drug to fight Duchenne muscular dystrophy. Find out why at least one expert says the study "delivered" great data.Digital Health Platform Lands Access to Hundreds of Thousands of Covered Lives
DarioHealth Corp. (DRIO:NASDAQ) signed a new agreement through its Amwell partnership that makes its cardiometabolic platform available to a major Arizona health insurer's ASO business, representing hundreds of thousands of covered lives.NASDAQ-Listed Duchenne Muscular Dystrophy Drugmaker Wins FDA Filing Acceptance Despite Confirmatory Trial Miss
Research Report
The FDA accepted the company's morpholino oligomer filings with a February 2027 PDUFA date, but a missed confirmatory trial endpoint clouds its path to full approval. 
Streetwise Key Charts
